HIgh Versus STAndard Blood Pressure Target in Hypertensive High-risk Patients Undergoing Major Abdominal Surgery
HISTAP
1 other identifier
interventional
636
1 country
18
Brief Summary
This study is a multicenter randomized controlled trial comparing two strategies of mean arterial blood pressure management (MAP ≥ 80mmHg vs MAP ≥ 65 mmHg) in high-risk surgical patients undergoing elective laparotomic/laparoscopic surgery.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Mar 2023
Typical duration for not_applicable
18 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 24, 2022
CompletedFirst Posted
Study publicly available on registry
December 5, 2022
CompletedStudy Start
First participant enrolled
March 6, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 21, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
May 21, 2025
CompletedJune 11, 2025
June 1, 2025
2.2 years
November 24, 2022
June 8, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Composite endpoint of postoperative mortality and at least one major organ dysfunction (see description in the secondary outcomes).
Composite postoperative outcome
up to 30 days after operation
Secondary Outcomes (8)
Hospital stay (days)
up to 30 days after operation
ICU stay (days)
up to 30 days after operation
ICU readmission
up to 30 days after operation
Sequential Organ Failure Assessment (SOFA) scores on postoperative
up to 7 days after operation
Overall intraoperative fluid balance
day 1 after the operation
- +3 more secondary outcomes
Other Outcomes (5)
CARDIOVASCULAR complications
day 7 after operation
NEUROLOGICAL complications
day 7 after operation
RESPIRATORY
day 7 after operation
- +2 more other outcomes
Study Arms (2)
MAP 80
EXPERIMENTALIntervention group: intraoperative mean blood pressure target \> 80 mmHg. Treatment of hypotension (defined as a mean blood pressure of below 80 mmHg) using intravenous bolus or continuous infusion of vasopressors, or fluids using a dedicated algorithm considering the pulse pressure or stroke volume variation and the mini fluid challenge to optimize mean blood pressure values.
MAP 65
OTHERControl group: intraoperative mean blood pressure target \> 65 mmHg. Treatment of hypotension (defined as a mean blood pressure of below 65 mmHg) using intravenous bolus or continuous infusion of vasopressors, or fluids using a dedicated algorithm considering the pulse pressure or stroke volume variation and the mini fluid challenge to optimize mean blood pressure values.
Interventions
In both the group, the target MAP can be maintained by means of bolus of ephedrine (2.5 mg). The maximal dose for the ephedrine allowed is 25 mg (10 boluses of 2.5 mg), after this threshold a continuous infusion of norepinephrine will be started
In both the group, the target MAP can be maintained by means of bolus of ephedrine (2.5 mg) or Etilefrine (1 mg). The continuous infusion of norepinephrine, as decided by the attending anesthetist, may be started at any point of the intraoperative period. The starting dose of norepinephrine is the lowest needed to reach the predefined MAP target.
The maximal dose for the etilefrine allowed is 10 mg (10 boluses of 1 mg), after this threshold a continuous infusion of norepinephrine will be started
PPV, SVV and mini\_FC will guide fluid bolus administration during an episode of intraoperative hypotension, following two predefined algorithms for laparotomic/non laparotomic surgery
Eligibility Criteria
You may qualify if:
- Adult patients ≥ 60 years
- History of chronic hypertension requiring home therapy.
- Scheduled for major elective abdominal surgery (laparoscopic, robotic or laparotomic)
- Expected surgical duration of at least 3 hours.
- Needing invasive arterial and hemodynamic monitoring as decided by the attending anesthetist, according to the rules of good clinical practice of each involved center.
- AND
- At increased risk of postoperative complications (at least one of the following):
- American Society of Anesthesiologists (ASA) class 3 or 4
- Known or documented history of coronary artery disease (angina, myocardial infarction or acute coronary syndrome).
- Known or documented history of peripheral vascular disease.
- Known or documented history of heart failure requiring treatment.
- Ejection fraction less than 30% (echocardiography)
- Signs of diastolic moderate to severe dysfunction or chronic hypertensive cardiomyopathy (echocardiography)
- Moderate or severe valvular heart disease (echocardiography)
- Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) Radiographically confirmed or according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria.
- +5 more criteria
You may not qualify if:
- Refusal of consent
- Chronic kidney disease with glomerular filtration rate \<30 ml/min/1.73 m2 or requiring renal-replacement therapy for end-stage renal disease
- Acute cardiovascular event, including acute or decompensated heart failure and acute coronary syndrome (within prior 30 days).
- Urgent or time-critical surgery
- Aortic or Renal vascular surgery (including nephrectomy)
- Liver Surgery
- Neurosurgery
- Surgery for palliative treatment only or ASA physical status 5
- Pregnancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (18)
Ospedali Riuniti Foggia- Università di Foggia
Foggia, Apulia, Italy
Department of Anesthesia and Intensive Care, University Hospital of Modena
Modena, Emilia-Romagna, Italy
Policlinico A. Gemelli
Rome, Lazio, Italy
Humanitas Research Hospital
Rozzano, MILANO, 20089, Italy
Fondazione Istituto San Raffaele G. Giglio
Cefalù, Sicily, Italy
Careggi University Hospital
Florence, Tuscany, 50134, Italy
Unit of Anesthesiology and Intensive Care B, Department of Surgery, Dentistry, Gynecology and Pediatrics, AOUI-University Hospital Integrated Trust of Verona
Verona, Veneto, Italy
Azienda Ospedaliero - Universitaria SS. Antonio e Biagio e Cesare Arrigo
Alessandria, Italy
ASST Grande Ospedale Metropolitano Niguarda
Milan, Italy
Istituto Nazionale dei Tumori
Milan, Italy
Ospedale Antonio Cardarelli
Napoli, Italy
Azienda sanitaria Friuli Occidentale (AsFO]
Pordenone, Italy
Ospedale Santo Stefano
Prato, Italy
Ospedale S. Anna di Castelnovo ne' Monti
Reggio Emilia, Italy
Sant'Eugenio ASL Roma 2:
Roma, Italy
Azienda Ospedaliero Universitaria di Sassari
Sassari, Italy
Ospedale Molinette
Torino, Italy
Ospedale Santa Chiara di Trento
Trento, Italy
Related Publications (2)
Messina A, Robba C, Calabro L, Zambelli D, Iannuzzi F, Molinari E, Scarano S, Battaglini D, Baggiani M, De Mattei G, Saderi L, Sotgiu G, Pelosi P, Cecconi M. Association between perioperative fluid administration and postoperative outcomes: a 20-year systematic review and a meta-analysis of randomized goal-directed trials in major visceral/noncardiac surgery. Crit Care. 2021 Feb 1;25(1):43. doi: 10.1186/s13054-021-03464-1.
PMID: 33522953BACKGROUNDWalsh M, Devereaux PJ, Garg AX, Kurz A, Turan A, Rodseth RN, Cywinski J, Thabane L, Sessler DI. Relationship between intraoperative mean arterial pressure and clinical outcomes after noncardiac surgery: toward an empirical definition of hypotension. Anesthesiology. 2013 Sep;119(3):507-15. doi: 10.1097/ALN.0b013e3182a10e26.
PMID: 23835589BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Antonio Messina
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, Italy
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Masking Details
- The trial intervention is not blinded for investigators, clinical staff, and patients, as blinding intraoperative MAP target is not feasible. The physicians of each center assessing all postoperative outcomes will be masked for the allocation.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
November 24, 2022
First Posted
December 5, 2022
Study Start
March 6, 2023
Primary Completion
May 21, 2025
Study Completion
May 21, 2025
Last Updated
June 11, 2025
Record last verified: 2025-06